News
Premier Beats Earnings Targets
Premier(NASDAQ:PINC) reported fourth quarter and full-year 2025 results on August 19, 2025, with revenue of $986 million and adjusted EPS of $1.54, both exceeding guidance. The company’s Supply
Medtronic Posts 7 Percent Growth in Q1
Medtronic (NYSE:MDT), a global medical technology leader specializing in cardiovascular, neuroscience, and surgical devices, reported Q1 FY2026 earnings on August 19, 2025. The most notable news
If You'd Invested $1,000 in UnitedHealth Group 3 Years Ago, Here's How Much You'd Have Today
UnitedHealth Group (NYSE: UNH) has been a staple in the healthcare world for decades and is one of the largest companies in the world, with a market cap of around $280 billion as of Aug. 18
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in
EQS-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2025
Why Voyager Technologies Stock Skyrocketed on AI News Today
Space and defense stock Voyager Technologies (NYSE: VOYG) took off like a rocket packed with fuel on Monday. The company's shares gained more than 13% in value after it divulged an investment into
Why Viking Therapeutics Stock Zoomed 5% Higher Today
Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week.
The clinical-stage biotech
Why UnitedHealth Stock Pushed Higher on Monday
UnitedHealth Group (NYSE: UNH), by far the health insurance stock that's gotten most of the market's attention over the past few trading sessions, had a good Monday on the exchange. Its shares added
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares
1 Beaten-Down Stock That Could Soar by the End of the Year
Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies.
That's
3 Fantastic Growth Stocks to Buy in August
We're well into the home stretch of 2025. August is more than halfway over. But there's still plenty of time remaining in the year -- and in this month -- to invest in stocks that hold the potential
2 Top Dividend Stocks to Buy on the Dip
Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.
Investors looking for companies that fit
2 Stocks to Buy on the Dip and Hold for 10 Years
Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (SNPINDEX: ^GSPC) up 10% since January
What AMD and Nvidia Shareholders Should Know About Recent China Updates
In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the
ImmuCell Q2 Profit Jumps as Margins Rise
ImmuCell(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million
Is This Beaten-Down Stock a Buy on the Dip?
Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX). The company's shares fell by
2 Dividend Stocks to Buy and Hold
We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines
What AMD, CoreWeave, and Nvidia Stock Investors Should Know About Recent Updates
In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and CoreWeave (NASDAQ: CRWV). To learn more, check out the short video, consider
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine resulted in the business posting record sales and profits in 2022. But
UnitedHealth's Dividend Yield Has Never Been This High. Should You Buy the Stock?
UnitedHealth Group (NYSE: UNH) has been a solid dividend growth stock for years. Generally, its yield has been fairly low, due to the stock's rising value. Even as the healthcare insurance giant has
TuHURA R&D Jumps 75% in Q2
TuHURA Biosciences (NASDAQ:HURA), a biotechnology company focused on immuno-oncology therapies, released its second quarter results on August 14, 2025. The big headlines included the start of a
ImmuCell Posts 18% Gain in Q2
ImmuCell (NASDAQ:ICCC), a specialist in animal health products for the dairy and beef industries, issued its earnings results for the second quarter of fiscal 2025 on August 14, 2025. The company
Tvardi Posts Q2 Net Income Turnaround
Tvardi Therapeutics (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on developing new therapies for serious diseases, released its second quarter fiscal 2025 results on August 14